[Early treatment of a Bence-Jones-kappa-light-chain-paraproteinemia].
Bethge
W A
WA
Abteilung für Hämatologie/Onkologie/Immunologie und Rheumatologie, Medizinische Universitätsklinik II, Tübingen. wolfgang.bethge@med.uni-tuebingen.de
Einsele
H
H
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001536:Bence Jones Protein / Q000378:metabolism*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D010265:Paraproteinemias / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D011239:Prednisolone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001536:Bence Jones Protein; D011239:Prednisolone; D008558:Melphalan